This case suggested that YES1 amplification might be associated with primary resistance to EGFR‐TKIs and that YES1 amplification might be a negative predictor of EGFR‐TKI treatment in NSCLC patients harboring EGFR sensitive mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.